# Intravitreal Aflibercept for Neovascular Polypoidal Choroidal Vasculopathy (RIVAL Trial)

> **NCT02092532** · PHASE4 · UNKNOWN · sponsor: **Southeast Retina Center, Georgia** · enrollment: 20 (estimated)

## Conditions studied

- Neovascular Polypoidal Choroidal Vasculopathy

## Interventions

- **DRUG:** Rescue Intravitreal Aflibercept Injection
- **PROCEDURE:** Rescue Therapy with PDT, Laser or Intravitreal Steroids

## Key facts

- **NCT ID:** NCT02092532
- **Lead sponsor:** Southeast Retina Center, Georgia
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2014-03
- **Primary completion:** 2015-03
- **Final completion:** 2016-03
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2014-10-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02092532

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02092532, "Intravitreal Aflibercept for Neovascular Polypoidal Choroidal Vasculopathy (RIVAL Trial)". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT02092532. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*